MISSION® pLKO.1-puro Non-Target shRNA Control Transduction Particles

Targets no known genes from any species

negative shRNA control, shRNA control, negative control, non-target shRNA, MISSION TurboGFP Control Transduction Particles, non-target control, non-target shRNA control
Pricing and availability is not currently available.

product line



≥1x106 VP/ml (via p24 assay)

shipped in

dry ice

storage temp.


Looking for similar products? Visit Product Comparison Guide

General description

The MISSION® pLKO.1-puro Non-Target shRNA Control Transduction Particles contain an shRNA insert that does not target any known genes from any species, making it useful as a negative control in experiments using the MISSION® shRNA library clones. This allows one to examine the effect of transduction of a short-hairpin on gene expression and interpret the knockdown effect seen with shRNA clones. Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. The Non-Target shRNA Control Transduction Particles are provided as 200 μL at 1 x 106 TU/mL via p24 assay.
When conducting experiments using MISSION® shRNA clones, the proper controls should be a key element of your experimental design to allow for accurate interpretation of knockdown results. The MISSION Control Transduction Particles are a critical positive control to monitor transduction efficiency.
To see more application data, protocols, vector maps visit


MISSION® pLKO.1-puro Non-Target shRNA Control Transduction Particles have been used to generate 3T3-L1 (pre-adipocytes) control cell lines.

Analysis Note

To see more application data, protocols, vector maps visit

Legal Information

MISSION is a registered trademark of Sigma-Aldrich Co. LLC


UN 3245 9

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

SIRT6 Depletion Suppresses Tumor Growth by Promoting Cellular Senescence Induced by DNA Damage in HCC.
Lee N
PLoS ONE, 11(11), e0165835-e0165835 (2016)
Namgyu Lee et al.
PloS one, 11(11), e0165835-e0165835 (2016-11-09)
The role of Sirtuin 6 (SIRT6) as a tumor suppressor or oncogene in liver cancer remains controversial. Thus, we identified the specific role of SIRT6 in the progression of hepatocellular carcinoma (HCC). SIRT6 expression was significantly higher in HCC cell...
Hedgehog associated to microparticles inhibits adipocyte differentiation via a non-canonical pathway.
Fleury A
Scientific Reports, 6 (2016)
Tomoko Ohashi et al.
Cancer letters, 390, 58-66 (2017-01-18)
The tumor suppressor gene p53 is frequently mutated in human cancer. p53 executes various functions, such as apoptosis induction and cell cycle arrest, by modulating transcriptional regulation. In this study, LIM domain and Actin-binding protein 1 (LIMA1) was identified as...
Zilong Yan et al.
Journal of cancer research and clinical oncology, 145(5), 1147-1164 (2019-02-17)
This study aimed at investigating the function and significance of CD110 expression in pancreatic cancer. We performed immunohistochemical staining for CD110 expression in tumor samples from 86 patients with pancreatic cancer. We evaluated clinical outcomes and other clinicopathological factors to...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.